Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavapadon - Cerevel Therapeutics

Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: CVL 751; PF 6649751; PF-06649751

Latest Information Update: 06 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antidementias; Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 23 Jul 2021 Cerevel Therapeutics completes a phase I trial in Parkinson's Disease (Adjunctive treatment) in USA (PO) (NCT04295642)
  • 24 Feb 2021 Phase-III clinical trials in Parkinson's disease in Bulgaria, Poland (PO) (NCT04760769) (EudraCT2019-002952-17)
  • 24 Feb 2021 Cerevel Therapeutics initiates enrolment in a phase III trial for Parkinson's disease in Germany, Hungary, Czech Republic, Australia and USA (NCT04760769) (EudraCT2019-002952-17)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top